low - Clinical trial timelines and FDA approval processes are largely insulated from GDP fluctuations. However, financing environment affects ability to raise capital for trials and commercialization. Oncology drug demand is non-discretionary and recession-resistant, though payer reimbursement negotiations can tighten during economic stress.

High sensitivity through valuation multiple compression rather than operational impact. Rising rates increase discount rates applied to distant cash flows (2028+ revenue), disproportionately affecting pre-revenue biotechs trading on NPV of pipeline. 10-year Treasury moves directly impact biotech sector multiples. Additionally, higher rates increase cost of future equity raises needed to fund $200M+ commercialization investment. Fed policy shifts can trigger 20-40% sector-wide biotech volatility.

growth/momentum - Attracts high-risk biotech specialists and event-driven funds focused on binary clinical catalysts. The 349% one-year return and 165% three-month surge indicates momentum-driven trading around trial milestones. Institutional ownership likely concentrated in healthcare-focused hedge funds and biotech ETFs rather than broad index funds. Not suitable for income or value investors given no revenue, negative cash flow, and valuation based entirely on discounted future earnings 3-5 years out.